IgA coating of vaginal bacteria is reduced in the setting of bacterial vaginosis (BV) and preferentially targets BV-associated species
Immunoglobulin (Ig) bacterial coating has been described in the gastrointestinal tract and linked to inflammatory bowel disease; however, little is known about Ig coating of vaginal bacteria and whether it plays a role in vaginal health including bacterial vaginosis (BV). We examined Ig coating in 18 women with symptomatic BV followed longitudinally before, 1 week, and 1 month after oral metronidazole treatment. Immunoglobulin A (IgA) and/or immunoglobulin G (IgG) coating of vaginal bacteria was assessed by flow cytometry, and Ig coated and uncoated bacteria were sorted and characterized using 16S rRNA sequencing. Despite higher levels of IgG compared to IgA in cervicovaginal fluid, the predominant Ig coating the bacteria was IgA. The majority of bacteria were uncoated at all visits, but IgA coating significantly increased after treatment for BV. Despite similar amounts of uncoated and IgA coated majority taxa ( >1% total) across all visits, there was preferential IgA coating of minority taxa (0.2%-1% total) associated with BV including Sneathia, several Prevotella species, and others. At the time of BV, we identified a principal component (PC) driven by proinflammatory mediators that correlated positively with an uncoated BV-associated bacterial community and negatively with an IgA coated protective Lactobacillus bacterial community. The preferential coating of BV-associated species, increase in coating following metronidazole treatment, and positive correlation between uncoated BV-associated species and inflammation suggest that coating may represent a host mechanism designed to limit bacterial diversity and reduce inflammatory responses. Elucidating the role of Ig coating in vaginal mucosal immunity may promote new strategies to prevent recurrent BV.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:92 |
|---|---|
| Enthalten in: |
Infection and immunity - 92(2024), 1 vom: 16. Jan., Seite e0037323 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Murphy, Kerry [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
140QMO216E |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 10.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1128/iai.00373-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365903191 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365903191 | ||
| 003 | DE-627 | ||
| 005 | 20240210232956.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/iai.00373-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM365903191 | ||
| 035 | |a (NLM)38099624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Murphy, Kerry |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a IgA coating of vaginal bacteria is reduced in the setting of bacterial vaginosis (BV) and preferentially targets BV-associated species |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Immunoglobulin (Ig) bacterial coating has been described in the gastrointestinal tract and linked to inflammatory bowel disease; however, little is known about Ig coating of vaginal bacteria and whether it plays a role in vaginal health including bacterial vaginosis (BV). We examined Ig coating in 18 women with symptomatic BV followed longitudinally before, 1 week, and 1 month after oral metronidazole treatment. Immunoglobulin A (IgA) and/or immunoglobulin G (IgG) coating of vaginal bacteria was assessed by flow cytometry, and Ig coated and uncoated bacteria were sorted and characterized using 16S rRNA sequencing. Despite higher levels of IgG compared to IgA in cervicovaginal fluid, the predominant Ig coating the bacteria was IgA. The majority of bacteria were uncoated at all visits, but IgA coating significantly increased after treatment for BV. Despite similar amounts of uncoated and IgA coated majority taxa ( >1% total) across all visits, there was preferential IgA coating of minority taxa (0.2%-1% total) associated with BV including Sneathia, several Prevotella species, and others. At the time of BV, we identified a principal component (PC) driven by proinflammatory mediators that correlated positively with an uncoated BV-associated bacterial community and negatively with an IgA coated protective Lactobacillus bacterial community. The preferential coating of BV-associated species, increase in coating following metronidazole treatment, and positive correlation between uncoated BV-associated species and inflammation suggest that coating may represent a host mechanism designed to limit bacterial diversity and reduce inflammatory responses. Elucidating the role of Ig coating in vaginal mucosal immunity may promote new strategies to prevent recurrent BV | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BV | |
| 650 | 4 | |a Ig-SEQ | |
| 650 | 4 | |a IgA | |
| 650 | 4 | |a IgA coating | |
| 650 | 4 | |a bacterial vaginosis | |
| 650 | 4 | |a dysbiosis | |
| 650 | 4 | |a vaginal microbiome | |
| 650 | 7 | |a Metronidazole |2 NLM | |
| 650 | 7 | |a 140QMO216E |2 NLM | |
| 650 | 7 | |a Immunoglobulin A |2 NLM | |
| 650 | 7 | |a RNA, Ribosomal, 16S |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Gromisch, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Srinivasan, Sujatha |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Lianna |e verfasserin |4 aut | |
| 700 | 1 | |a Proll, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Congzhou |e verfasserin |4 aut | |
| 700 | 1 | |a Fiedler, Tina |e verfasserin |4 aut | |
| 700 | 1 | |a Valint, D J |e verfasserin |4 aut | |
| 700 | 1 | |a Fredricks, David N |e verfasserin |4 aut | |
| 700 | 1 | |a Keller, Marla J |e verfasserin |4 aut | |
| 700 | 1 | |a Herold, Betsy C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection and immunity |d 1970 |g 92(2024), 1 vom: 16. Jan., Seite e0037323 |w (DE-627)NLM000004278 |x 0019-9567 |7 nnns |
| 773 | 1 | 8 | |g volume:92 |g year:2024 |g number:1 |g day:16 |g month:01 |g pages:e0037323 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/iai.00373-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 92 |j 2024 |e 1 |b 16 |c 01 |h e0037323 | ||